An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B

CSL Behring

Summary

The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).

Eligibility

Age range: 18+ years
Sex: Male
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: Received treatment with CSL222 in Study CSL222\_2001 or Study CSL222\_3001, and completed participation in Study CSL222\_2001 or Study CSL222\_3001 or at least 5 years have passed since receiving CSL222. Exclusion Criteria: Not Applicable

Interventions

Locations (28)

10-15 Phoenix Childrens Hospital
Phoenix, Arizona
10-14 Arkansas Children's Hospital - Pharmacology
Little Rock, Arkansas
10-22 Orthopaedic Institute for Children
Los Angeles, California
10-21 Children's Hospital of Los Angeles
Los Angeles, California
10-63 UC Davis Medical Center
Sacramento, California
10-12 University of California, San Diego (UCSD)
San Diego, California